國立虎尾科技大學 |

Targeting the DNA damage response for anti-cancer therapy

紀錄類型:	書目-語言資料,印刷品 : Monograph/item
正題名/作者:	Targeting the DNA damage response for anti-cancer therapy/ edited by John Pollard, Nicola Curtin.
其他作者:	Pollard, John.
出版者:	Cham :Springer International Publishing : : 2018.,
面頁冊數:	ix, 401 p. :ill. (some col.), digital ; : 24 cm.;
Contained By:	Springer eBooks
標題:	Cancer - Treatment -
電子資源:	http://dx.doi.org/10.1007/978-3-319-75836-7
ISBN:	9783319758367

Targeting the DNA damage response for anti-cancer therapy
Targeting the DNA damage response for anti-cancer therapy[electronic resource] /edited by John Pollard, Nicola Curtin. - Cham :Springer International Publishing :2018. - ix, 401 p. :ill. (some col.), digital ;24 cm. - Cancer drug discovery and development,2196-9906. - Cancer drug discovery and development..

Over the past decade a complex role for DNA damage response (DDR) in tumorigenesis has emerged. A proficient DDR has been shown to be a primary cause for cellular resistance to the very many DNA damaging drugs, and IR, that are widely used as standard-of-care across multiple cancer types. It has also been shown that defects in this network, predominantly within the ATM mediated signaling pathway, are commonly observed in cancers and may be a primary event during tumorigenesis. Such defects may promote a genomically unstable environment, facilitating the persistence of mutations, any of which may provide a growth or survival advantage to the developing tumor. In addition, these somatic defects provide opportunities to exploit a reliance on remaining repair pathways for survival, a process which has been termed synthetic lethality. As a result of all these observations there has been a great interest in targeting the DDR to provide anti-cancer agents that may have benefit as monotherapy in cancers with high background DNA damage levels or as a means to increase the efficacy of DNA damaging drugs and IR. In this book we will review a series of important topics that are of great interest to a broad range of academic, industrial and clinical researchers, including the basic science of the DDR, its role in tumorigenesis and in dictating response to DNA damaging drugs and IR. Additionally, we will focus on the several proteins that have been targeted in attempts to provide drug candidates, each of which appear to have quite distinct profiles and could represent very different opportunities to provide patient benefit.

ISBN: 9783319758367

Standard No.: 10.1007/978-3-319-75836-7doiSubjects--Topical Terms:

861481
Cancer
--Treatment

LC Class. No.: RC270.8 / .T374 2018

Dewey Class. No.: 616.99406

Targeting the DNA damage response for anti-cancer therapy
LDR:02659nam a2200313 a 4500 001 926618
003 DE-He213
005 20181204094956.0
006 m d
007 cr nn 008maaau
008 190625s2018 gw s 0 eng d
020 $a 9783319758367 $q (electronic bk.)
020 $a 9783319758343 $q (paper)
024 7 $a 10.1007/978-3-319-75836-7 $2 doi
035 $a 978-3-319-75836-7
040 $a GP $c GP
041 0 $a eng
050 4 $a RC270.8 $b .T374 2018
072 7 $a MJCL $2 bicssc
072 7 $a MED062000 $2 bisacsh
082 0 4 $a 616.99406 $2 23
090 $a RC270.8 $b .T185 2018
245 0 0 $a Targeting the DNA damage response for anti-cancer therapy $h [electronic resource] / $c edited by John Pollard, Nicola Curtin.
260 $a Cham : $c 2018. $b Springer International Publishing : $b Imprint: Humana Press,
300 $a ix, 401 p. : $b ill. (some col.), digital ; $c 24 cm.
490 1 $a Cancer drug discovery and development, $x 2196-9906
520 $a Over the past decade a complex role for DNA damage response (DDR) in tumorigenesis has emerged. A proficient DDR has been shown to be a primary cause for cellular resistance to the very many DNA damaging drugs, and IR, that are widely used as standard-of-care across multiple cancer types. It has also been shown that defects in this network, predominantly within the ATM mediated signaling pathway, are commonly observed in cancers and may be a primary event during tumorigenesis. Such defects may promote a genomically unstable environment, facilitating the persistence of mutations, any of which may provide a growth or survival advantage to the developing tumor. In addition, these somatic defects provide opportunities to exploit a reliance on remaining repair pathways for survival, a process which has been termed synthetic lethality. As a result of all these observations there has been a great interest in targeting the DDR to provide anti-cancer agents that may have benefit as monotherapy in cancers with high background DNA damage levels or as a means to increase the efficacy of DNA damaging drugs and IR. In this book we will review a series of important topics that are of great interest to a broad range of academic, industrial and clinical researchers, including the basic science of the DDR, its role in tumorigenesis and in dictating response to DNA damaging drugs and IR. Additionally, we will focus on the several proteins that have been targeted in attempts to provide drug candidates, each of which appear to have quite distinct profiles and could represent very different opportunities to provide patient benefit.
650 0 $a Cancer $x Treatment $x Genetic aspects. $3 861481
650 0 $a DNA damage. $3 582916
650 1 4 $a Biomedicine. $3 593880
650 2 4 $a Cancer Research. $3 668358
650 2 4 $a Gene Therapy. $3 580629
700 1 $a Pollard, John. $3 1205290
700 1 $a Curtin, Nicola. $3 1205291
710 2 $a SpringerLink (Online service) $3 593884
773 0 $t Springer eBooks
830 0 $a Cancer drug discovery and development. $3 887663
856 4 0 $u http://dx.doi.org/10.1007/978-3-319-75836-7
950 $a Medicine (Springer-11650)